News & Events
Biocept and Insight Genetics Collaborate to Advance Non-Small Cell Lung Cancer Diagnosis and Treatment
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs); and Insight Genetics, a leading molecular diagnostic assay development company, today announced their collaboration to generate an enhanced diagnostic for the expression and mutation of ALK, a major therapeutic target in the treatment of non-small cell lung cancer.
Insight Genetics presented a poster at the San Antonio Breast Cancer Symposium (SABCS) on December 13, 2014, in Hall C from 7:30-9:00a.m. The poster, titled “Creation of a robust algorithm utilizing minimal gene sets normalized against a reference gene set to identify triple-negative breast cancer (TNBC) subtypes,” highlighted Insight Genetics work with the Vanderbilt Ingram Cancer Center (VICC) on developments in subtyping triple-negative breast cancer for the treatment and diagnosis of TNBC patients.
Insight Genetics presented at QIAGEN’s workshop at the Association for Molecular Pathology Annual Meeting on new developments and challenges in anaplastic lymphoma kinase (ALK) testing for the advancement of precision medicine for lung cancer patients. QIAGEN’s corporate workshop was held on Nov.12, 2014, at 2pm at the Gaylord National Resort & Convention Center in National Harbor, Maryland.
Insight Genetics was selected to present at the National Cancer Institute’s Small Business Innovation Research (SBIR) Investor Forum in Santa Clara, Calif., on Nov. 13, 2014. The annual event fosters new relationships and partnerships with top SBIR-funded companies that are on the brink of commercializing innovative cancer-related technologies.